MX343687B - Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. - Google Patents
Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.Info
- Publication number
- MX343687B MX343687B MX2013012922A MX2013012922A MX343687B MX 343687 B MX343687 B MX 343687B MX 2013012922 A MX2013012922 A MX 2013012922A MX 2013012922 A MX2013012922 A MX 2013012922A MX 343687 B MX343687 B MX 343687B
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- making
- same
- sulfonamide compounds
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Abstract
La invención provee compuestos sulfonamida tricíclicos y su uso en el tratamiento de trastornos médicos, tales como obesidad; se proveen composiciones farmacéuticas y métodos para hacer diversos compuestos tricíclicos; se contempla que los compuestos tengan actividad contra la metionil aminopeptidasa 2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161483265P | 2011-05-06 | 2011-05-06 | |
PCT/US2012/036792 WO2012154678A1 (en) | 2011-05-06 | 2012-05-07 | Tricyclic sulfonamide compounds and methods of making and using same |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013012922A MX2013012922A (es) | 2014-02-27 |
MX343687B true MX343687B (es) | 2016-11-16 |
Family
ID=46147039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013012922A MX343687B (es) | 2011-05-06 | 2012-05-07 | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. |
Country Status (10)
Country | Link |
---|---|
US (2) | US9187494B2 (es) |
EP (1) | EP2705036B1 (es) |
JP (1) | JP5941981B2 (es) |
KR (1) | KR20140053013A (es) |
CN (1) | CN103748094B (es) |
AU (1) | AU2012253759B2 (es) |
BR (1) | BR112013028665A2 (es) |
CA (1) | CA2835195A1 (es) |
MX (1) | MX343687B (es) |
WO (1) | WO2012154678A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
AU2010303270A1 (en) | 2009-10-09 | 2012-05-03 | Zafgen Corporation | Sulphone compounds for use in the treatment of obesity |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
CA2786603C (en) | 2010-01-08 | 2018-02-20 | James E. Vath | Fumagillol type compounds and methods of making and using same |
WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
BR112013001613A2 (pt) | 2010-07-22 | 2016-05-24 | Zafgen Inc | compostos tricíclicos e métodos para fazer e usar os mesmos. |
US9221787B2 (en) | 2010-10-12 | 2015-12-29 | Zafgen, Inc. | Sulphonamine compounds and methods of making and using same |
JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン,インコーポレイテッド | 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
CA2825408A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
US9328082B2 (en) | 2011-03-08 | 2016-05-03 | Zafgen, Inc. | Oxaspiro[2.5]octane derivatives and analogs |
EP2705036B1 (en) | 2011-05-06 | 2015-08-12 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
AU2012253757B2 (en) | 2011-05-06 | 2017-04-13 | Zafgen Inc. | Partially saturated tricyclic compounds and methods of making and using same |
WO2012154679A1 (en) * | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
EP2763671A2 (en) | 2011-10-03 | 2014-08-13 | Zafgen, Inc. | Methods of treating age related disorders |
JP6035347B2 (ja) | 2012-01-18 | 2016-11-30 | ザフゲン,インコーポレイテッド | 三環式スルホンアミド化合物ならびにその作製および使用方法 |
CA2861381A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
EP2846792B1 (en) | 2012-05-08 | 2018-08-15 | Zafgen, Inc. | Treating hypothalamic obesity with metap2 inhibitors |
EP2850079B1 (en) | 2012-05-09 | 2018-05-02 | Zafgen, Inc. | Fumigillol type compounds and methods of making and using same |
US10174009B2 (en) | 2012-11-05 | 2019-01-08 | Zafgen, Inc. | Tricyclic sulphonamide compounds and methods of making and using same |
BR112015010196A2 (pt) | 2012-11-05 | 2017-07-11 | Zafgen Inc | métodos de tratar doença do fígado |
KR20150080614A (ko) | 2012-11-05 | 2015-07-09 | 자프겐 인크. | 비만의 치료 및/또는 제어에서 사용하기 위한 트리시클릭 화합물 |
WO2014152861A2 (en) | 2013-03-14 | 2014-09-25 | Zafgen, Inc. | Methods of treating renal disease and other disorders |
EP2978764B1 (en) * | 2013-03-25 | 2017-04-19 | Sanofi | Pyrazolonaphthyridinone derivatives as metap2 inhibitors (methionine aminopeptidase type-2) |
CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
WO2017044569A1 (en) * | 2015-09-09 | 2017-03-16 | Icahn School Of Medicine At Mount Sinai | Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents |
SG11201908012SA (en) * | 2017-03-02 | 2019-09-27 | Assembly Biosciences Inc | Cyclic sulfamide compounds and methods of using same |
CN115286560A (zh) * | 2022-07-28 | 2022-11-04 | 五邑大学 | 一种吲哚亚胺并环戊烯类化合物的合成方法 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164410A (en) | 1988-01-09 | 1992-11-17 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
PH26256A (en) | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
KR0138530B1 (ko) | 1988-09-01 | 1998-05-15 | 우메모또 요시마사 | 푸마길롤 유도체 |
US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
US5180738A (en) | 1988-09-01 | 1993-01-19 | Takeda Chemical Industries | Fumagillol derivatives and pharmaceutical compositions thereof |
US5288722A (en) | 1989-03-06 | 1994-02-22 | Takeda Chemical Industries, Ltd. | 6-amino-6-desoxyfumagillols, production and use thereof |
ATE87623T1 (de) | 1989-03-06 | 1993-04-15 | Takeda Chemical Industries Ltd | 6-epifumagillole, ihre herstellung und ihre verwendung. |
US5290807A (en) | 1989-08-10 | 1994-03-01 | Children's Medical Center Corporation | Method for regressing angiogenesis using o-substituted fumagillol derivatives |
US6017954A (en) | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
EP0415294A3 (en) | 1989-08-31 | 1991-06-12 | Takeda Chemical Industries, Ltd. | Cyclohexanol derivatives, production and use thereof |
TW282399B (es) | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
US5238950A (en) | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
DE69330690T2 (de) | 1992-01-30 | 2002-06-20 | Takeda Chemical Industries Ltd | Verfahren zur Herstellung hoch-wasserlöslicher Zyklodextrinkomplexe |
ATE153854T1 (de) | 1992-12-16 | 1997-06-15 | Takeda Chemical Industries Ltd | Stabile pharmazeutische zubereitung mit fumagillolderivaten |
JP3260378B2 (ja) | 1995-03-27 | 2002-02-25 | サノフィーサンテラボ | 腸感染に対する薬物の調製のためのフマギロールおよびその誘導体の使用 |
CA2234401A1 (en) | 1995-10-11 | 1997-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Vascular permeation inhibitor |
EP0799616A1 (en) | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
AU3968597A (en) | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
US6281245B1 (en) | 1996-10-28 | 2001-08-28 | Versicor, Inc. | Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof |
CA2283272A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
US7115632B1 (en) | 1999-05-12 | 2006-10-03 | G. D. Searle & Co. | Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
ES2224465T3 (es) | 1997-10-31 | 2005-03-01 | Children's Medical Center Corporation | Metodo para regular el tamaño y el crecimiento del tejido normal vascularizado. |
DE69827664T2 (de) | 1997-12-23 | 2005-12-08 | Warner-Lambert Co. Llc | Thioharnstoffverbindungen, zusammensetzungen sowie verfahren zur behandlung oder verhütung von entzündlichen erkrankungen und atherosklerose |
US6242494B1 (en) | 1998-05-01 | 2001-06-05 | Abbott Laboratories | Substituted β-amino acid inhibitors of methionine aminopeptidase-2 |
KR100357541B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 5-데메톡시 푸마질롤 유도체 및 그 제조방법 |
KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
JP2000116337A (ja) | 1998-10-09 | 2000-04-25 | Nippon Shokuhin Kako Co Ltd | ペットフード |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
DE60027420T2 (de) | 1999-04-28 | 2006-11-16 | Aventis Pharma Deutschland Gmbh | Tri-aryl-säurederivate als ppar rezeptor liganden |
AU7989400A (en) | 1999-10-01 | 2001-05-10 | Smithkline Beecham Corporation | Compounds and methods |
US20020002152A1 (en) | 2000-04-14 | 2002-01-03 | Craig Richard A. | Hydrazide and alkoxyamide angiogenesis inhibitors |
US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
AR030631A1 (es) | 2000-09-29 | 2003-08-27 | Abbott Lab | Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis |
EP1330447A2 (en) | 2000-11-01 | 2003-07-30 | Praecis Pharmaceuticals Incorporated | Peptides as met-ap2 inhibitors |
US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
ES2329553T4 (es) | 2000-12-20 | 2010-12-07 | Bristol-Myers Squibb Company | Pirroloquinolinas y piridoquinolinas sustituidas como agonistas y antagonistas de serotonina. |
US20040116495A1 (en) | 2001-03-29 | 2004-06-17 | Marino Jr. Joseph P. | Compounds and methods |
US20020183242A1 (en) | 2001-04-11 | 2002-12-05 | Jack Henkin | Peptide antiangiogenic drugs |
DE60233420D1 (de) | 2001-09-27 | 2009-10-01 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
US7119120B2 (en) | 2001-12-26 | 2006-10-10 | Genzyme Corporation | Phosphate transport inhibitors |
KR100451485B1 (ko) | 2002-03-28 | 2004-10-06 | 주식회사종근당 | 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물 |
US6989392B2 (en) | 2002-06-18 | 2006-01-24 | Abbott Laboratories | 2-Aminoquinolines as melanin concentrating hormone receptor antagonists |
US7030262B2 (en) | 2002-08-06 | 2006-04-18 | Abbott Laboratories | 3-Amino-2-hydroxyalkanoic acids and their prodrugs |
US20040067266A1 (en) | 2002-10-07 | 2004-04-08 | Toppo Frank R. | Weight loss compound |
US20040068012A1 (en) | 2002-10-08 | 2004-04-08 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US7491718B2 (en) * | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
AU2004203977B2 (en) | 2003-01-09 | 2010-06-17 | Pfizer Inc. | Diazepinoindole derivatives as kinase inhibitors |
US20040204472A1 (en) | 2003-03-04 | 2004-10-14 | Pharmacia Corporation | Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents |
ATE403650T1 (de) | 2003-08-08 | 2008-08-15 | Janssen Pharmaceutica Nv | 2- (chinoxalin-5-ylsulfonylamino) - benzamidverbindungen als cck2-modulatoren |
AR046330A1 (es) | 2003-09-09 | 2005-12-07 | Japan Tobacco Inc | Inhibidor de dipeptidilpeptidasa iv |
CA2550689A1 (en) | 2003-12-22 | 2005-07-14 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2-benzisothiazoles, and preparation and uses thereof |
JP2007537147A (ja) | 2003-12-29 | 2007-12-20 | プレーシス ファーマスーティカルズ インコーポレイテッド | メチオニンアミノペプチダーゼ−2のインヒビターおよびその使用 |
KR100552043B1 (ko) | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
WO2005113513A2 (en) | 2004-05-12 | 2005-12-01 | Chemocentryx | Aryl sulfonamides |
JP2008505176A (ja) | 2004-06-30 | 2008-02-21 | コンビナトアールエックス インコーポレーティッド | 代謝障害を治療するための方法および試薬 |
US20060045865A1 (en) | 2004-08-27 | 2006-03-02 | Spherics, Inc. | Controlled regional oral delivery |
AU2005289887A1 (en) | 2004-09-24 | 2006-04-06 | Janssen Pharmaceutica, N.V. | Sulfonamide compounds |
WO2006080591A1 (en) | 2005-01-26 | 2006-08-03 | Chong Kun Dang Pharmaceutical Corp. | Fumagillol derivatives or method for preparation of fumagillol derivatives, and pharmaceutical compositions comprising the same |
FR2886855B1 (fr) | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
US20070078172A1 (en) | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
AU2006330587B2 (en) | 2005-12-23 | 2012-12-13 | Glaxosmithkline Llc | Azaindole inhibitors of aurora kinases |
WO2008008374A2 (en) | 2006-07-14 | 2008-01-17 | Chemocentryx, Inc. | Ccr2 inhibitors and methods of use thereof |
DE102007020492A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
AU2008268262C1 (en) | 2007-06-26 | 2015-02-19 | Children's Medical Center Corporation | MetAP-2 inhibitor polymersomes for therapeutic administration |
US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
EA020251B1 (ru) | 2007-11-28 | 2014-09-30 | Мерсана Терапьютикс, Инк. | Биосовместимые и биоразлагаемые конъюгаты аналогов фумагиллина |
DE502008003324D1 (de) | 2007-11-30 | 2011-06-01 | Bayer Schering Pharma Ag | Heteroaryl-substituierte piperidine |
CA2731020A1 (en) | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Use of antiangiogenic fumagillins in the treatment of obesity |
ES2641471T3 (es) | 2008-10-06 | 2017-11-10 | The Johns Hopkins University | Compuestos de quinolina como inhibidores de la angiogénesis, metionina aminopeptidasa humana, y SirT1, y procedimientos de tratamiento de trastornos |
US8906896B2 (en) | 2008-10-24 | 2014-12-09 | Ulrich Bierbach | Platinum acridine anti-cancer compounds and methods thereof |
US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
US20120010290A1 (en) | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
US20120010259A1 (en) | 2008-12-04 | 2012-01-12 | Vath James E | Methods of Treating an Overweight or Obese Subject |
AU2010303270A1 (en) | 2009-10-09 | 2012-05-03 | Zafgen Corporation | Sulphone compounds for use in the treatment of obesity |
US8815309B2 (en) | 2010-01-08 | 2014-08-26 | Zafgen, Inc. | Methods of treating a subject with benign prostate hyperplasia |
US20130023513A1 (en) | 2010-01-12 | 2013-01-24 | Hughes Thomas E | Methods and Compositions for Treating Cardiovascular Disorders |
WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
US20130210821A1 (en) | 2010-05-27 | 2013-08-15 | James E. Vath | Methods for Treating Obesity |
BR112013001613A2 (pt) | 2010-07-22 | 2016-05-24 | Zafgen Inc | compostos tricíclicos e métodos para fazer e usar os mesmos. |
US9221787B2 (en) | 2010-10-12 | 2015-12-29 | Zafgen, Inc. | Sulphonamine compounds and methods of making and using same |
UA111479C2 (uk) | 2010-11-09 | 2016-05-10 | Зафджен, Інк. | Кристалічні форми інгібітору metap-2 та способи їх отримання і застосування |
WO2012064928A1 (en) | 2010-11-10 | 2012-05-18 | Zafgen Corporation | Methods and compositions for treating thyroid hormone related disorders |
WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
WO2012075026A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of treating obesity using an effective dose of a metap-2 inhibitor |
JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン,インコーポレイテッド | 6−o−(4−ジメチルアミノエトキシ)シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
CA2825408A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
EP2705036B1 (en) | 2011-05-06 | 2015-08-12 | Zafgen Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
AU2012253757B2 (en) | 2011-05-06 | 2017-04-13 | Zafgen Inc. | Partially saturated tricyclic compounds and methods of making and using same |
WO2012154679A1 (en) | 2011-05-06 | 2012-11-15 | Zafgen Corporation | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
WO2013033430A1 (en) | 2011-09-02 | 2013-03-07 | Wake Forest School Of Medicine | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
-
2012
- 2012-05-07 EP EP12722592.8A patent/EP2705036B1/en active Active
- 2012-05-07 CN CN201280032366.6A patent/CN103748094B/zh not_active Expired - Fee Related
- 2012-05-07 KR KR1020137032334A patent/KR20140053013A/ko not_active Application Discontinuation
- 2012-05-07 US US14/116,026 patent/US9187494B2/en not_active Expired - Fee Related
- 2012-05-07 JP JP2014509511A patent/JP5941981B2/ja not_active Expired - Fee Related
- 2012-05-07 CA CA2835195A patent/CA2835195A1/en not_active Abandoned
- 2012-05-07 WO PCT/US2012/036792 patent/WO2012154678A1/en active Application Filing
- 2012-05-07 AU AU2012253759A patent/AU2012253759B2/en not_active Ceased
- 2012-05-07 MX MX2013012922A patent/MX343687B/es active IP Right Grant
- 2012-05-07 BR BR112013028665A patent/BR112013028665A2/pt not_active IP Right Cessation
-
2015
- 2015-10-08 US US14/878,428 patent/US9561230B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2705036B1 (en) | 2015-08-12 |
AU2012253759A8 (en) | 2013-12-05 |
US9561230B2 (en) | 2017-02-07 |
AU2012253759A1 (en) | 2013-11-21 |
CA2835195A1 (en) | 2012-11-15 |
JP2014513139A (ja) | 2014-05-29 |
CN103748094A (zh) | 2014-04-23 |
KR20140053013A (ko) | 2014-05-07 |
JP5941981B2 (ja) | 2016-06-29 |
AU2012253759B2 (en) | 2016-01-21 |
US20140073623A1 (en) | 2014-03-13 |
US9187494B2 (en) | 2015-11-17 |
WO2012154678A1 (en) | 2012-11-15 |
MX2013012922A (es) | 2014-02-27 |
EP2705036A1 (en) | 2014-03-12 |
BR112013028665A2 (pt) | 2016-09-06 |
CN103748094B (zh) | 2016-06-29 |
US20160256469A1 (en) | 2016-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX343687B (es) | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. | |
MX343688B (es) | Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso. | |
MX345535B (es) | Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso. | |
MX2014008706A (es) | Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos. | |
MX2014008705A (es) | Compuestos tricíclicos de sulfona y métodos para elaborarlos y utilizarlos. | |
MX339201B (es) | Compuestos de sulfonamida y métodos para elaborarlos y usarlos. | |
MX344238B (es) | Compuestos de tetrazol y métodos para preparar y usar los mismos. | |
MX343135B (es) | Compuestos de tipo fumagilol y métodos de realización y uso de los mismos. | |
BR112013001613A2 (pt) | compostos tricíclicos e métodos para fazer e usar os mesmos. | |
MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
TN2015000278A1 (en) | Autotaxin inhibitors | |
GB201118656D0 (en) | New compounds | |
IN2013CN01340A (es) | ||
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
MX343706B (es) | Derivados heterocíclicos novedosos. | |
MX349004B (es) | Nuevos compuestos. | |
MX2015005732A (es) | Compuestos tricíclicos y métodos para hacer y utilizar los mismos. | |
PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
MX2015014083A (es) | Inhibidores de enzima de escision de proteina precursora beta-amiloide (app) en el sitio beta 1 (bace1). | |
PH12014502623B1 (en) | Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors | |
CY1116234T1 (el) | Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3 | |
TN2014000046A1 (en) | Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one | |
UY33219A (es) | Cetoenoles cíclicos para terapias | |
GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |